Table 2 Change from baseline in lung function parameters after 52 weeks
Placebo | Reslizumab | 52-week treatment difference (reslizumab vs placebo) (95% CI) | p value | |||
|---|---|---|---|---|---|---|
Baseline | Change at 52 weeks | Baseline | Change at 52 weeks | |||
≥ 400 EOS < 14% reversibility group | ||||||
N | 52 | 42 | 64 | 52 | ||
FEV1, mL | 2339 (107) | 265 (98) | 1945 (92) | 439 (105) | 174 (1 to 348) | 0.0493 |
FEV1% predicted | 73.3 (2.6) | 6.7 (3.2) | 67.4 (2.2) | 13.8 (3.4) | 7.1 (1.4 to 12.7) | 0.0144 |
FVC, mL | 3.5 (0.14) | 271 (121) | 2.9 (0.13) | 419 (129) | 148 (− 65 to 362) | 0.1714 |
FEF25–75%, mLa | 1.7 (0.14) | 297 (133) | 1.3 (0.090) | 444 (141) | 147 (− 88 to 383) | 0.2172 |
Overall population excluding the ≥ 400 EOS < 14% reversibility group | ||||||
N | 424 | 358 | 413 | 365 | ||
FEV1, mL | 1919 (35) | 130 (37) | 2018 (38) | 270 (36) | 139 (76 to 202) | < 0.0001 |
FEV1% predicted | 65.7 (0.94) | 4.7 (1.2) | 66.8 (1.0) | 9.1 (1.2) | 4.4 (2.3 to 6.5) | < 0.0001 |
FVC, mL | 2.9 (0.049) | 157 (46) | 3.1 (0.049) | 288 (45) | 131 (52 to 210) | 0.0013 |
FEF25–75%, mLb | 1.7 (0.29) | 79 (53) | 1.4 (0.043) | 207 (51) | 128 (39 to 217) | 0.0047 |